Buprenorphine/naloxone sublingual spray - INSYS Therapeutics

Drug Profile

Buprenorphine/naloxone sublingual spray - INSYS Therapeutics

Alternative Names: Naloxone/buprenorphine sublingual spray - INSYS Therapeutics

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSYS Therapeutics, Inc
  • Class Antidotes; Cyclopropanes; Drug withdrawal therapies; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists; Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Opioid abuse

Most Recent Events

  • 17 Oct 2016 Phase-II clinical trials in Opioid abuse in USA (Sublingual) (Insys Therapeutics pipeline, October 2016)
  • 01 Jun 2015 INSYS Therapeutics initiates a phase I trial (In volunteers) in USA (NCT02477267)
  • 12 Jan 2015 Phase-I clinical trials in Opioid abuse in USA before January 2015 (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top